The authors of this paper review the various methods of safety biomarker discovery and development, and challenge researchers to advance the use of safety biomarkers that are indicative of drug-induced toxicity. This type of research typically spans both preclinical and clinical development programs. Having the ability to identify translational safety biomarkers on the same technology platform is one of Myriad RBM’s strengths.
